Suppr超能文献

含1,2,3-三唑的化合物作为抗肺癌药物:当前进展、作用机制及构效关系

1,2,3-Triazole-Containing Compounds as Anti-Lung Cancer Agents: Current Developments, Mechanisms of Action, and Structure-Activity Relationship.

作者信息

Liang Ting, Sun Xiangyang, Li Wenhong, Hou Guihua, Gao Feng

机构信息

Key Laboratory for Experimental Teratology of the Ministry of Education and Biomedical Isotope Research Center, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.

Department of Interventional Radiology, Qilu Hospital of Shandong University, Jinan, China.

出版信息

Front Pharmacol. 2021 Jun 11;12:661173. doi: 10.3389/fphar.2021.661173. eCollection 2021.

Abstract

Lung cancer is the most common malignancy and leads to around one-quarter of all cancer deaths. Great advances have been achieved in the treatment of lung cancer with novel anticancer agents and improved technology. However, morbidity and mortality rates remain extremely high, calling for an urgent need to develop novel anti-lung cancer agents. 1,2,3-Triazole could be readily interact with diverse enzymes and receptors in organisms through weak interaction. 1,2,3-Triazole can not only be acted as a linker to tether different pharmacophores but also serve as a pharmacophore. This review aims to summarize the recent advances in 1,2,3-triazole-containing compounds with anti-lung cancer potential, and their structure-activity relationship (SAR) together with mechanisms of action is also discussed to pave the way for the further rational development of novel anti-lung cancer candidates.

摘要

肺癌是最常见的恶性肿瘤,约占所有癌症死亡人数的四分之一。新型抗癌药物和改进技术在肺癌治疗方面取得了巨大进展。然而,发病率和死亡率仍然极高,迫切需要开发新型抗肺癌药物。1,2,3-三唑可通过弱相互作用与生物体内的多种酶和受体轻松相互作用。1,2,3-三唑不仅可以作为连接不同药效基团的连接体,还可以作为药效基团。本综述旨在总结含1,2,3-三唑的具有抗肺癌潜力的化合物的最新进展,并讨论它们的构效关系(SAR)及其作用机制,为进一步合理开发新型抗肺癌候选药物铺平道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b7b/8226129/8f5dcb66a558/fphar-12-661173-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验